- Home
- AHG vs DNTH Comparison
AHG vs DNTH Comparison
Compare AHG & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHG
- DNTH
- Stock Information
- Founded
- AHG 2013
- DNTH 2015
- Country
- AHG China
- DNTH United States
- Employees
- AHG N/A
- DNTH N/A
- Industry
- AHG Business Services
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- AHG Consumer Discretionary
- DNTH Health Care
- Exchange
- AHG Nasdaq
- DNTH Nasdaq
- Market Cap
- AHG 650.1M
- DNTH 657.0M
- IPO Year
- AHG N/A
- DNTH N/A
- Fundamental
- Price
- AHG $1.47
- DNTH $17.35
- Analyst Decision
- AHG
- DNTH Strong Buy
- Analyst Count
- AHG 0
- DNTH 8
- Target Price
- AHG N/A
- DNTH $53.00
- AVG Volume (30 Days)
- AHG 20.8K
- DNTH 255.5K
- Earning Date
- AHG 06-06-2025
- DNTH 05-12-2025
- Dividend Yield
- AHG N/A
- DNTH N/A
- EPS Growth
- AHG N/A
- DNTH N/A
- EPS
- AHG N/A
- DNTH N/A
- Revenue
- AHG $8,454,946.00
- DNTH $6,524,000.00
- Revenue This Year
- AHG N/A
- DNTH N/A
- Revenue Next Year
- AHG N/A
- DNTH N/A
- P/E Ratio
- AHG N/A
- DNTH N/A
- Revenue Growth
- AHG 281.19
- DNTH 102.36
- 52 Week Low
- AHG $0.62
- DNTH $13.37
- 52 Week High
- AHG $2.35
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- AHG 48.09
- DNTH 37.87
- Support Level
- AHG $1.54
- DNTH $16.91
- Resistance Level
- AHG $1.98
- DNTH $18.45
- Average True Range (ATR)
- AHG 0.21
- DNTH 1.12
- MACD
- AHG -0.01
- DNTH -0.20
- Stochastic Oscillator
- AHG 13.56
- DNTH 19.57
About AHG Akso Health Group ADS
Akso Health Group formerly Xiaobai Maimai Inc is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.